2024 年 04 月 17 日 荣泰健康(603579) 目标价: 昨收盘:21.87 | --- | --- | --- | --- | --- | |-------|-----------------------------------------|------------------------------------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders for Q1 2024 to be between 59.25 million and 64.58 million yuan, an increase of 21.75 million to 27.08 million yuan compared to the same period last year, representing a year-on-year increase of 58.00% to 72.22%[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 57.55 million and 62.89 million yuan, an increase of 31.69 million to 37.02 million yuan compared to the same period last year, representing a year-on-year increase of 122.50% to 143.11%[5]. - The net profit for the same period last year was 37.50 million yuan, and the net profit after deducting non-recurring gains and losses was 25.87 million yuan[6]. Factors Influencing Performance - The company attributes the performance increase to the recovery of consumer demand and the optimization of product structure, as well as the expansion of domestic and international market share[7]. - The company emphasizes that there are no significant uncertainties affecting the accuracy of this performance forecast[8]. Reporting and Disclosure - The forecast data is preliminary and the final financial data will be disclosed in the official Q1 2024 report[9].

Financial Performance - Revenue for 2023 was 1.855 billion yuan, a decrease of 7.47% compared to the previous year[3] - Net profit attributable to shareholders was 202.71 million yuan, an increase of 23.43% year-on-year[3] - Net profit attributable to shareholders after deducting non-recurring gains and losses was 186.47 million yuan, an increase of 47.78% year-on-year[3] - The company's basic earnings per share were 1.51 yuan, an increase of 22.76% compared to the previous year[4] - The company's weighted average return on equity was 10.50%, an increase of 1.42 percentage points year-on-year[4] - Revenue for Q1 2023 was RMB 385.72 million, Q2 was RMB 504.18 million, Q3 was RMB 408.17 million, and Q4 was RMB 556.95 million[34] - Net profit attributable to shareholders in Q1 2023 was RMB 37.50 million, Q2 was RMB 67.42 million, Q3 was RMB 46.82 million, and Q4 was RMB 50.97 million[34] - Non-recurring gains and losses for 2023 totaled RMB 16.24 million, compared to RMB 38.04 million in 2022 and RMB 101.70 million in 2021[38] - Revenue decreased year-over-year, but profitability and profit margins improved significantly due to favorable exchange rates and lower raw material prices[42] - Company achieved consolidated operating revenue of 1,855,029,390.81 yuan, a year-on-year decrease of 7.47%[101] - Net profit attributable to the parent company was 202,706,851.03 yuan, a year-on-year increase of 23.43%[101] - Manufacturing sector revenue decreased by 7.10% to 1,839,119,919.42 RMB, with a gross margin increase of 4.00 percentage points to 30.63%[107] - Service sector revenue decreased by 8.61% to 6,041,520.32 RMB, with a gross margin increase of 39.14 percentage points to 66.74%[107] - Total revenue decreased by 7.10% to 1,845,161,439.74 RMB, with a gross margin increase of 4.11 percentage points to 30.74%[107] - Massage chair revenue decreased by 5.90% to 1,766,407,013.60 RMB, with a gross margin increase of 4.22 percentage points to 31.12%[107] - Small appliance revenue decreased by 28.22% to 72,109,722.82 RMB, with a gross margin decrease of 2.61 percentage points to 19.07%[107] - Top 5 customers accounted for 44.13% of total annual sales, totaling 818,697,800 RMB[111] - Top 5 suppliers accounted for 24.21% of total annual procurement, totaling 245,178,300 RMB[111] - Merchant service revenue decreased by 69.22% to 1,066,603.99 yuan, accounting for 53.08% of total revenue[121] - Direct material costs for massage chairs decreased by 13.04% to 993,968,434.26 yuan, accounting for 81.69% of total costs[121] - Total costs for massage chairs decreased by 11.33% to 1,216,732,886.15 yuan[121] - Direct material costs for small electrical appliances decreased by 25.62% to 56,421,849.75 yuan, accounting for 96.68% of total costs[121] - Total costs for small electrical appliances decreased by 25.83% to 58,359,840.21 yuan[121] - Accounts receivable increased by 61.29% to 153,334,053.36 yuan, accounting for 4.53% of total assets[128] - Short-term borrowings decreased by 68.39% to 129,132,300.71 yuan, accounting for 3.81% of total assets[128] - Other equity investments increased by 212.74% to 93,508,800.00 yuan, accounting for 2.76% of total assets[128] - Estimated liabilities increased by 95.01% to 71,577,930.47 yuan, accounting for 2.11% of total assets[128] - The company's total assets as of December 31, 2023, were 3.385 billion yuan, with a debt-to-asset ratio of 41.71% and a credit rating of AA-[197] R&D and Innovation - The company completed 15 R&D projects, added 15 invention patents, 67 utility model patents, 11 design patents, and 11 software copyrights[1] - The company's S80 massage chair won the 2023 MUSE Design Gold Award, and the RT7730 massage chair won the 2023 MUSE Design Silver Award[1] - R&D expenses were 80,176,150.48 yuan, a year-on-year decrease of 9.57%[102] - The company has 182 R&D personnel, accounting for 16.61% of the total workforce[113] - The company is focusing on AI technology, health detection management, and voice interaction to drive innovation in massage chair technology and maintain a competitive edge[140] - The company aims to create a full product matrix of massage chairs, including ultra-high-end, mid-to-high-end, light luxury, and simple models, to enhance competitiveness in various market segments[140] - The company plans to acquire health-related companies with AI capabilities to integrate emerging technologies like cloud computing and big data into its products[141] - The company is enhancing its R&D capabilities and production automation to develop new products and expand its customer base both domestically and internationally[139] Overseas Expansion and Market Strategy - The company plans to establish a factory in Thailand, with a memorandum of cooperation signed with Suvarnabhumi Asia Industrial Park[2] - The company's online direct sales revenue on Douyin achieved rapid growth[15] - Overseas markets showed mixed performance: South Korea recovered in the second half, the US saw a slight decline, while Europe, the Middle East, and Southeast Asia remained stable, with Russia showing significant growth[46] - The company adjusted its European and Southeast Asian market teams by splitting them into two independent teams to better meet customer needs and explore market potential[46] - The company has expanded its overseas market, with products sold to the US, EU, South Korea, Southeast Asia, and countries along the Belt and Road[99] - The company plans to expand its overseas market presence by developing potential markets in Southeast Asia and Europe, and selling its own brand massage chairs and small appliances through e-commerce platforms like Amazon[140] - The company is establishing an overseas production base in Thailand's Suvarnabhumi Asia Industrial Park to better respond to global uncertainties and effectively expand its international market[140] - The company's export business involves direct sales to overseas clients, who then determine the brand, sales channels, and pricing for the products[83] Cost Control and Efficiency - The company's logistics cost control was effective, with a significant reduction in cargo damage rates[2] - Direct material costs decreased by 13.87% to 1.051 billion RMB, accounting for 82.38% of total manufacturing costs[44] - Manufacturing expenses decreased by 3.77% to 88.617 million RMB, accounting for 6.95% of total manufacturing costs[44] - The company implemented cost reduction and efficiency improvement measures, including optimizing supply chain management and reducing unnecessary expenses[42] - The company is improving production efficiency and supply chain management to reduce unit costs through economies of scale[142] - Depreciation costs decreased by 69.00% to 26,727.34 yuan, accounting for 1.33% of total costs[121] Cash Flow and Financial Activities - Operating cash flow increased by 45.40% to 344.295 million RMB, while financing cash flow decreased by 327.18% to 426.170 million RMB[58] - Net cash flow from operating activities was 344,294,659.84 yuan, a year-on-year increase of 45.40%[102] - Net cash flow from investing activities was 120,962,648.98 yuan, compared to -225,043,933.29 yuan in the same period last year[104] - Net cash flow from financing activities was -426,170,282.03 yuan, a year-on-year decrease of 327.18%[104] - The company plans to use idle funds to purchase financial products and manage cash from convertible bonds in 2023[165] - The company will engage in forward exchange and foreign exchange derivative business in 2023[165] - The company plans to sign financing agreements with banks and use idle funds for financial product purchases in 2023[174] Product Portfolio and Sales Channels - The company optimized its product portfolio through product innovation and customization to meet the needs of different markets and channels[42] - The company's main products include massage chairs and small massage devices, with massage chairs providing a full-body massage experience through software-controlled hardware, and small devices focusing on specific body parts[63] - The company operates in the domestic market through five sales channels: distribution, direct sales, e-commerce, experience stores, and ODM, while its export business primarily uses FOB terms[75][76] - As a leading domestic and global manufacturer of massage chairs, the company has over 1,000 offline stores in China and a strong presence on major e-commerce platforms like Tmall, JD.com, and Suning[77] - The company employs a brand differentiation strategy, with the "Rongtai" brand targeting mid-to-high-end massage chairs and the "Momoda" brand focusing on entry-level products[77] - The company has established a multi-channel marketing strategy, including shopping malls, chain stores, car 4S stores, e-commerce, and experience stores[97] Industry and Market Trends - The massage equipment industry in China has grown from RMB 55.819 billion in 2014 to RMB 95.119 billion in 2023, with the household sector accounting for 56.77% of the market in 2023[80] - In 2023, the company produced 191,760 massage chairs, a decrease of 5.75% year-over-year, and sold 268,344 units, a decrease of 6.25% year-over-year[86] - The company's sales of small massage devices in 2023 were 335,595 units, a decrease of 33.57% year-over-year, with inventory decreasing by 4.03%[86] - The company's performance is driven by increasing demand for health-related products, aging populations, and younger consumers seeking relief from work-related stress[85] Investments and Subsidiaries - Other equity instrument investments increased by RMB 63.61 million in 2023, reaching RMB 93.51 million at year-end[40] - Transactional financial assets decreased by RMB 37.93 million in 2023, ending at RMB 15.11 million[40] - Other non-current financial assets increased by RMB 4.48 million in 2023, totaling RMB 99.55 million at year-end[40] - Transactional financial liabilities increased by RMB 7.46 million in 2023, reaching RMB 12.08 million[40] - The total impact of financial asset and liability changes on 2023 profits was a loss of RMB 11.05 million[40] - Shanghai Rongtai Health Technology Co., Ltd. invested 138.9966 million RMB in Shanghai Miaoyin Network Technology Co., Ltd., achieving a 100% ownership[132] - The company invested 4,750 million RMB in Shanghai Rongchang Lingsi Commercial Factoring Co., Ltd., holding a 95% stake[132] - Shanghai Rongtai Health Technology Co., Ltd. invested 167.31 million RMB in Shaoxi Network Technology Co., Ltd., with a 75% ownership[132] - The company invested 3.5 million USD in BODYFRIEND, INC., holding a 35% stake[132] - Shanghai Rongtai Health Technology Co., Ltd. invested 90 million RMB in Guangdong Momole Network Technology Co., Ltd., with a 30% ownership before exiting in November 2023[132] - The company invested 1,764.50 million RMB in Guangzhou Jinno Intelligent Equipment Co., Ltd., holding a 20% stake[132] - Shanghai Rongtai Health Technology Co., Ltd. invested 920 million KRW in BAHC CO., LTD., with a 7.7% ownership[132] - The company invested 1,885 million RMB in Jiaxing Ouyuan Motor Co., Ltd., holding a 35% stake[132] - Shanghai Rongtai Health Technology Co., Ltd. invested 532.65 million RMB in Shanghai Rongyi Electric Appliance Co., Ltd., achieving 100% ownership[132] - The company invested 200 million RMB in Guangdong Kaixuan Sports Goods Co., Ltd., with a 10% ownership[132] Corporate Governance and Shareholder Relations - The company's 2023 annual general meeting approved several key resolutions, including the 2022 annual report, financial report, and profit distribution plan[165] - The company's board of directors approved the 2022 annual report, financial report, and profit distribution plan during the fourth meeting[174] - The company will not adjust the conversion price of "Rongtai Convertible Bonds" in 2023[174] - The company's board of directors held 9 meetings in the year, with all directors attending all meetings either in person or via communication methods[177] - The Audit Committee held 4 meetings during the reporting period, reviewing the company's annual report and providing relevant suggestions[178] - The company's cash dividend policy for 2024 includes a distribution of RMB 10.00 per 10 shares and a capital reserve transfer of 3 shares per 10 shares[181] - In 2023, the company repurchased and canceled 1 million restricted shares, accounting for 0.71% of the total share capital, due to unmet performance conditions[183] - The company's 2021 restricted stock incentive plan's second unlocking period did not meet performance conditions, resulting in the cancellation of 1 million shares[183] - The company's 2021 management partner shareholding plan's second vesting period also did not meet performance conditions, with corresponding shares to be sold and proceeds returned to the company[183] - The company's salary policy includes different structures for production and non-production staff, with future adjustments based on Shanghai's average wage and company performance[180] - The company's cash dividend policy is in compliance with the articles of association, with clear standards, complete decision-making procedures, and protection of minority shareholders' rights[182] - The company's board of directors and audit committee have been diligent in their duties, with no instances of directors missing two consecutive meetings[177][178] - The company has a cumulative cash dividend payout ratio of 38.99% over the past three years and plans to maintain a stable dividend policy[190] Environmental and Social Responsibility - The company and its subsidiaries have implemented carbon reduction measures, reducing CO2 emissions by 2,193.29 tons[185] - The company has built a 1.7MWp distributed rooftop photovoltaic project, generating approximately 1.81 million kWh annually and reducing CO2 emissions by 1,491.44 tons[185] - Subsidiary Zhejiang Rongtai has built an 800KWp distributed rooftop photovoltaic project, generating approximately 850,000 kWh annually and reducing CO2 emissions by 701.85 tons[186] - The company has maintained a stable production and operation, with steady output value and profit, and has obtained multiple quality and safety certifications[189] - The company has established a comprehensive training system, including the development of the Rongtai University E-learning platform, to enhance employee skills and knowledge[195] - The company has actively participated in community civilization construction, forming partnerships with multiple local organizations and achieving a satisfaction rate of over 95%[199] - The company has consistently engaged in disaster relief and donation activities, being recognized as an advanced unit for voluntary blood donation for 10 consecutive years[200] Human Resources and Compensation - Total compensation for directors, supervisors, and senior management in 2023 was 9.0656 million yuan[153] - The company has a total of 1,096 employees, with 651 production personnel, 104 sales personnel, 182 technical personnel, 36 financial personnel, and 123 administrative personnel[159] - The company's educational composition includes 26 employees with a master's degree or above, 272 with a bachelor's degree, 291 with an associate degree, and 507 with education below an associate degree[159] - The total hours of outsourced labor were 1.9895 million hours, with a total payment of 57.1434 million yuan[160] - The company distributed cash dividends of 26.25 million yuan in 2016, 39.375 million yuan in 2015, and 26.25 million yuan in 2014[161] Risk Management and Strategic Goals - The company faces risks from a high concentration of revenue from its major client, BODYFRIEND, which accounted for a significant portion of its main business revenue[163] - The company is actively developing new products with ODM partners and expanding its market presence in Europe and America beyond South Korea[163] - The company is implementing multiple measures to address industry competition, focusing on product innovation and maintaining a strong brand image[164] - The company's strategic goal is to become a leading international fashion health appliance service provider by leveraging its existing technological, market, and production advantages[139] - The company is committed to innovation in products, services, and business models to optimize global residents' quality of life and achieve sustainable growth[139] - The company is leveraging capital markets to raise funds for expanding production scale and improving technological innovation[139]

Group 1: Company Overview - The company, Shanghai Rongtai Health Technology Co., Ltd., has seen growth in both domestic and overseas markets in Q4 2023, with revenue and performance increasing year-on-year and quarter-on-quarter [5] - The company operates approximately 1,200 stores, focusing on improving the quality of existing stores rather than merely increasing quantity [9] Group 2: Financial Performance - The overall target for 2024 is to achieve over 20% growth in both revenue and profit [6] - The company reported a sales figure of approximately 5 million RMB from products in collaboration with Xiaomi during Q4 2023 [10] Group 3: Market Insights - Online sales in 2023 are primarily direct sales, with Tmall accounting for about 40%, JD.com for 25%, and Douyin for 30% of online revenue [7] - The company has observed a polarization in consumer behavior, with high-end (20,000-30,000 RMB) and low-end (3,000-4,000 RMB) massage chairs seeing increased sales, while mid-range products (around 10,000 RMB) have declined [10] Group 4: International Operations - Export revenue breakdown: South Korea accounts for approximately 55%, the USA for 28%, and Europe and Southeast Asia for 17% [13] - The company is planning to establish a factory in Thailand to address potential tariff issues and expand its presence in Southeast Asia [17] Group 5: Customer and Product Strategy - The target demographic is primarily women aged 30-45, with a trend towards younger consumers [12] - The company has not acquired new clients recently but is actively seeking opportunities through exhibitions and direct outreach [15] Group 6: Financial Management - The company has implemented currency hedging against USD fluctuations, with minimal impact on foreign exchange gains and losses in Q4 2023 [17] - There are no immediate plans for new financing, as the company has sufficient internal funds [17] Group 7: Shareholder Engagement - The company conducts regular cash dividends for investors, with the distribution ratio adjusted based on annual performance [18] - A new round of equity incentives is under discussion, following a recent share buyback [18] Group 8: Convertible Bonds - The company’s convertible bonds have seen limited conversion activity over the past three years, and there are no current plans to adjust the conversion price [19]

Financial Performance - The company's operating revenue for Q3 2023 was approximately ¥408.17 million, a decrease of 11.44% compared to the same period last year[3]. - Net profit attributable to shareholders of the listed company reached approximately ¥46.82 million, an increase of 19.13% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was approximately ¥38.61 million, up 29.38% from the previous year[3]. - Basic earnings per share for the quarter were ¥0.35, reflecting a 16.67% increase compared to the same period last year[5]. - Total revenue for the first three quarters of 2023 was CNY 1,298,074,815.73, a decrease of 17% compared to CNY 1,562,236,538.61 in the same period of 2022[20]. - Net profit for the first three quarters of 2023 was CNY 152,477,626.53, an increase of 21% from CNY 126,203,740.32 in the same period of 2022[21]. - Earnings per share for the first three quarters of 2023 were CNY 1.13, compared to CNY 0.94 in the same period of 2022[22]. - The total comprehensive income for the first three quarters of 2023 was CNY 200,265,076.43, compared to CNY 124,702,935.30 in the same period of 2022[22]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥3.29 billion, a decrease of 4.04% from the end of the previous year[5]. - Total liabilities as of the end of Q3 2023 amounted to CNY 1,283,371,531.81, a decrease from CNY 1,553,734,654.79 at the end of Q3 2022[20]. - Total equity as of the end of Q3 2023 was CNY 2,002,225,578.68, an increase from CNY 1,870,090,507.23 at the end of Q3 2022[20]. - As of September 30, 2023, the company's total current assets decreased to RMB 2,064,140,891.69 from RMB 2,270,578,335.21 at the end of 2022, representing a decline of approximately 9.1%[14]. - The total assets of the company decreased to RMB 3,285,597,110.49 from RMB 3,423,825,162.02, a decline of approximately 4.0%[16]. Cash Flow - The company reported a net cash flow from operating activities of approximately ¥145.61 million for the year-to-date, an increase of 5.42%[3]. - In the first three quarters of 2023, the cash inflow from operating activities was CNY 1,299,392,319.74, a decrease of 22.2% compared to CNY 1,669,609,011.22 in the same period of 2022[24]. - The net cash flow from operating activities in Q3 2023 was CNY 145,614,894.49, up 5.4% from CNY 138,125,272.35 in Q3 2022[25]. - Total cash outflow from operating activities in Q3 2023 was CNY 1,261,315,928.87, down 24.5% from CNY 1,671,808,671.90 in Q3 2022[25]. - The net cash flow from investing activities in Q3 2023 was -CNY 84,230,977.05, an improvement from -CNY 163,082,776.47 in Q3 2022[25]. - Cash inflow from financing activities in Q3 2023 was CNY 149,133,100.12, significantly lower than CNY 480,388,766.85 in Q3 2022[26]. - The net cash flow from financing activities in Q3 2023 was -CNY 369,269,914.53, compared to a positive net flow of CNY 130,313,798.82 in Q3 2022[26]. - The total cash and cash equivalents at the end of Q3 2023 was CNY 1,054,783,730.00, down from CNY 1,236,468,311.92 at the end of Q3 2022[26]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,759[10]. - The largest shareholder, Lin Qi, holds 25.11% of the shares, totaling 34,900,230 shares[10]. Legal Matters - The company is currently involved in a legal dispute with a claim for economic damages of RMB 99 million related to patent infringement[12]. - The company has taken actions to actively respond to the lawsuit and is contesting the claims made by the plaintiff[13]. Inventory and Costs - The company reported a significant reduction in inventory, which decreased to RMB 167,777,464.37 from RMB 205,227,948.56, a decline of approximately 18.2%[14]. - Total operating costs for the first three quarters of 2023 were CNY 1,146,125,766.88, down 19% from CNY 1,422,054,592.18 in 2022[20]. - Research and development expenses for the first three quarters of 2023 were CNY 59,424,399.03, down from CNY 70,003,833.97 in the same period of 2022[20]. Other Financial Metrics - The weighted average return on equity was 2.43%, an increase of 0.28 percentage points compared to the previous year[5]. - The company achieved an investment income of CNY 24,529,034.40 in the first three quarters of 2023, significantly higher than CNY 9,950,483.06 in the same period of 2022[20]. - The company reported a financial income of CNY 12,553,774.04 for the first three quarters of 2023, compared to a loss of CNY 25,541,159.68 in the same period of 2022[20]. - The company experienced a foreign exchange gain of CNY 32,893,242.60 in Q3 2023, compared to CNY 21,867,302.08 in Q3 2022[26].

2023 年半年度报告 公司代码：603579 公司简称：荣泰健康 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 2023 年半年度报告 1 / 186 2023 年半年度报告 重要提示 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投资者注意投 资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人林琪、主管会计工作负责人廖金花及会计机构负责人（会计主管人员）贾晓丽声 明：保证半年度报告中财务报告的真实、准确、完整。 | 第一节 ...

2023 年第一季度报告 证券代码：603579 证券简称：荣泰健康 证券代码：113606 证券简称：荣泰转债 上海荣泰健康科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人林琪、主管会计工作负责人廖金花及会计机构负责人（会计主管人员）贾晓丽保证季 度报告中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同 期增减变动幅度(%) | | --- | --- | --- | | 营业收入 | 385,718,637.33 | -31.71 | | 归属于上市公司股东的净利润 | 37,501,251.13 | -35.70 | | 归属于上市公司股东的扣除非经常性损益的净利 | ...

2022年年度报告 公司代码：603579 公司简称：荣泰健康 转债代码：113606 转债简称：荣泰转债 荣泰，更专业的按摩椅 上海荣泰健康科技股份有限公司 2022 年年度报告 ...

2022 年第三季度报告 证券代码：603579 证券简称：荣泰健康 上海荣泰健康科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | 项目 | 本报告期 | 本报告期 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 比上年同 | | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 460,877,983.10 | -25.26 | 1,562,236,538.61 | -16.24 | | 归属于上市公司股东的 | 39,299,476.20 | -18.52 | 125,666,979.14 | -33.37 | | 净利润 | | | | | | 归属于上市公司股东的 ...

2022 年半年度报告 上海荣泰健康科技股份有限公司 2022 年半年度报告 1 / 179 无 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 公司代码：603579 公司简称：荣泰健康 转债代码：113606 转债简称：荣泰转债 三、 本半年度报告未经审计。 荣泰，更专业的按摩椅 四、 公司负责人林琪、主管会计工作负责人廖金花及会计机构负责人（会计主管人员）贾晓丽声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 八、 是否存在违反规定决策程序对外提供担保的情况？ 公司已在本报告中详细描述可能存在的相关风险,敬请查阅本报告第三节管理层讨论与分析 中可能面对的风险部分的内容。 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战 ...